Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06782659 · ClinicalTrials.gov registry record · Phase 1
Study to Compare the Effects of Viagra® Vs Hezkue® in Healthy Fasted Male Participants.
A Phase 1 study, sponsored by Aspargo Labs.
- Not yet
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT06782659: Clinical Trial Phase 1 study, sponsored by Aspargo Labs.
NCT06782659 is a Phase 1 study that has not yet begun recruiting, run by Aspargo Labs. The registered enrollment target is 56 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06782659, a Phase 1 study, has not yet begun recruiting, sponsored by Aspargo Labs.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The objective of this phase 1, open-label, single-center, two-way crossover trial is to evaluate the pharmacokinetics (PK), safety, and tolerability of 100 mg ASP-001 oral liquid suspension versus 100 mg Viagra (sildenafil citrate) tablets in fasted, healthy male volunteers
Primary Outcome
The PK profile of ASP-001 and Viagra in healthy male subjects. Calculation of maximum plasma concentration (Cmax) over the specified timeframe.
Interventions
- DRUG ASP-001
- DRUG Viagra
- DEVICE ASP-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2025-01 |
| Est. Completion | 2025-03 |
| Phase | Phase 1 |
What is known before NCT06782659 opens enrollment
NCT06782659 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which ASP-001 is the first listed.
NCT06782659 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06782659 about?
NCT06782659 is a clinical study titled "Study to Compare the Effects of Viagra® Vs Hezkue® in Healthy Fasted Male Participants.". The objective of this phase 1, open-label, single-center, two-way crossover trial is to evaluate the pharmacokinetics (PK), safety, and tolerability of 100 mg ASP-001 oral liquid suspension versus 100 mg Viagra (sildenafil citrate) tablets in fasted, healthy male volunteers
What is the current status of trial NCT06782659?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2025-01. Estimated completion is 2025-03.
What interventions are being tested in trial NCT06782659?
The interventions under investigation include: ASP-001 (DRUG), Viagra (DRUG), ASP-001 (DEVICE).
Who is sponsoring clinical trial NCT06782659?
This trial is sponsored by Aspargo Labs, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06782659's enrollment target sits among peer trials
56 902nd of 2000 higher than 1,083 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia